# Lantus (Insulin Glargine) Drug Interactions

## Drug Overview
- **Generic Name:** Insulin Glargine
- **Brand Names:** Lantus, Lantus SoloStar, Toujeo, Basaglar, Semglee, Rezvoglar
- **Drug Class:** Long-Acting Insulin Analog
- **Primary Uses:**
  - Type 1 Diabetes Mellitus (with short-acting insulin at meals)
  - Type 2 Diabetes Mellitus (basal insulin therapy)
- **Mechanism:** 
  - Long-acting insulin with relatively constant concentration over 24 hours
  - Forms microprecipitates after subcutaneous injection, providing slow, prolonged release
  - No pronounced peak (peakless profile)
  - Facilitates cellular glucose uptake and inhibits hepatic gluconeogenesis
- **FDA Approval:** 2000
- **Duration of Action:** ~24 hours (allows once-daily dosing)

---

## Critical Considerations for Lantus

### Do NOT Mix with Other Insulins
- **Important:** Lantus should NOT be diluted or mixed with any other insulin or solution
- **Reason:** Mixing can alter pharmacokinetic profile and glycemic effects
- **Management:** Administer as separate injection
- **Source:** FDA Prescribing Information

### Do NOT Use in Insulin Pumps
- **Important:** Lantus is NOT approved for use in insulin infusion pumps
- **Source:** FDA Prescribing Information

---

## Major Drug-Drug Interactions (Severity: HIGH - Significant Clinical Concern)

### 1. Pramlintide
- **Interacting Drug:** Pramlintide (Symlin)
- **Interaction Type:** Pharmacodynamic; administration requirement
- **Mechanism:** Both affect postprandial glucose; must be given separately
- **Clinical Effect:** Increased hypoglycemia risk; must NOT be mixed
- **Management:** 
  - Must be administered as separate injections
  - Reduce meal-time insulin (not Lantus) by 50% when initiating pramlintide
  - Lantus (basal) typically not reduced
- **Source:** FDA Prescribing Information; Medscape Drug Interactions

### 2. Thiazolidinediones (TZDs) - Heart Failure Risk
- **Interacting Drugs:** Pioglitazone (Actos), Rosiglitazone (Avandia)
- **Interaction Type:** Additive glucose lowering + fluid retention
- **Mechanism:** 
  - Both lower glucose
  - TZDs cause fluid retention; insulin may exacerbate
- **Clinical Effect:** 
  - Hypoglycemia
  - New or worsening heart failure
  - Peripheral edema
- **Management:**
  - Monitor for heart failure signs (weight gain, dyspnea, edema)
  - May need insulin dose reduction
  - Avoid in NYHA Class III-IV heart failure
- **Source:** FDA Prescribing Information (Lantus)

### 3. Disopyramide
- **Interacting Drug:** Disopyramide (Norpace)
- **Interaction Type:** Additive hypoglycemic effect
- **Mechanism:** Disopyramide has independent hypoglycemic properties
- **Clinical Effect:** Severe, unpredictable hypoglycemia
- **Management:** Close glucose monitoring; use alternative antiarrhythmic if possible
- **Source:** Drugs.com Drug Interactions Database

### 4. Pentamidine
- **Interacting Drug:** Pentamidine
- **Interaction Type:** Biphasic glucose effect
- **Mechanism:** Initially causes hypoglycemia by beta-cell toxicity, followed by hyperglycemia from beta-cell destruction
- **Clinical Effect:** Unpredictable, severe glucose swings
- **Management:** Extremely close glucose monitoring; may need insulin dose adjustments
- **Source:** FDA Prescribing Information (Lantus)

---

## Moderate Drug-Drug Interactions (Severity: MODERATE - Monitor Closely)

### Drugs That INCREASE Hypoglycemia Risk (Potentiate Insulin Effect)

#### Oral Antidiabetic Agents
- **Interacting Drugs:**
  - Sulfonylureas: Glipizide, Glimepiride, Glyburide
  - Meglitinides: Repaglinide, Nateglinide
  - SGLT2 Inhibitors: Empagliflozin (Jardiance), Dapagliflozin, Canagliflozin
  - GLP-1 Agonists: Semaglutide (Ozempic), Dulaglutide, Liraglutide
  - DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin
  - Metformin
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Increased hypoglycemia risk (especially with sulfonylureas/meglitinides)
- **Management:** 
  - Consider lower Lantus dose when combining
  - Reduce sulfonylurea/meglitinide when adding Lantus
  - Monitor glucose closely
- **Source:** FDA Prescribing Information; Medscape Drug Interactions

#### ACE Inhibitors
- **Interacting Drugs:** Lisinopril, Enalapril, Ramipril, Captopril, Benazepril, Fosinopril, Perindopril, Quinapril
- **Interaction Type:** Enhanced insulin sensitivity
- **Mechanism:** May improve insulin sensitivity
- **Clinical Effect:** Possible hypoglycemia
- **Management:** Monitor blood glucose; may need Lantus dose reduction
- **Source:** Medscape Drug Interactions; Drugs.com

#### Angiotensin II Receptor Blockers (ARBs)
- **Interacting Drugs:** Losartan, Valsartan, Irbesartan, Candesartan, Olmesartan, Eprosartan
- **Interaction Type:** May enhance insulin effects
- **Mechanism:** Unspecified mechanism
- **Clinical Effect:** Possible hypoglycemia
- **Management:** Monitor glucose; adjust Lantus as needed
- **Source:** Medscape Drug Interactions

#### Beta-Blockers
- **Interacting Drugs:** Propranolol, Metoprolol, Atenolol, Carvedilol, Bisoprolol, Labetalol, Nadolol
- **Interaction Type:** 
  - May mask hypoglycemia symptoms
  - Some may prolong hypoglycemia
  - Non-selective beta-blockers may inhibit insulin release
- **Mechanism:** 
  - Block adrenergic symptoms (tachycardia, tremor, anxiety)
  - Propranolol may prolong recovery from hypoglycemia
- **Clinical Effect:** 
  - Delayed recognition of hypoglycemia
  - Prolonged hypoglycemic episodes
- **Management:**
  - Patient education on recognizing hypoglycemia
  - More frequent glucose monitoring
  - Cardioselective beta-blockers (metoprolol, bisoprolol) preferred
- **Source:** FDA Prescribing Information (Lantus); Medical News Today

#### Salicylates (High-Dose)
- **Interacting Drugs:** Aspirin (>3g/day), Salsalate
- **Interaction Type:** Enhanced hypoglycemic effect
- **Mechanism:** Salicylates have intrinsic glucose-lowering properties
- **Clinical Effect:** Increased hypoglycemia risk
- **Management:** Monitor glucose with high-dose salicylate therapy
- **Source:** Drugs.com Drug Interactions Database

#### MAO Inhibitors
- **Interacting Drugs:** Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline
- **Interaction Type:** Enhanced hypoglycemic effect
- **Mechanism:** May increase insulin secretion and sensitivity
- **Clinical Effect:** Hypoglycemia
- **Management:** Close glucose monitoring; may need Lantus dose reduction
- **Source:** FDA Prescribing Information; Drugs.com

#### Fibric Acid Derivatives
- **Interacting Drugs:** Fenofibrate, Gemfibrozil
- **Interaction Type:** May enhance insulin effects
- **Clinical Effect:** Possible hypoglycemia
- **Management:** Monitor blood glucose
- **Source:** Drugs.com

#### Fluoxetine
- **Interacting Drug:** Fluoxetine (Prozac)
- **Interaction Type:** Enhanced insulin sensitivity
- **Mechanism:** Fluoxetine may improve insulin sensitivity
- **Clinical Effect:** Potential hypoglycemia
- **Management:** Monitor blood glucose
- **Source:** Drugs.com Drug Interactions Database

#### Other Antidepressants
- **Interacting Drugs:** Other SSRIs (sertraline, paroxetine), SNRIs
- **Interaction Type:** Variable glucose effects
- **Clinical Effect:** Generally minor; monitor glucose
- **Source:** Clinical literature

### Drugs That DECREASE Lantus Efficacy (May Cause Hyperglycemia)

#### Corticosteroids
- **Interacting Drugs:** Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Betamethasone, Budesonide (systemic)
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Increase hepatic gluconeogenesis; cause insulin resistance
- **Clinical Effect:** Significant hyperglycemia; loss of glycemic control
- **Management:**
  - May need substantial Lantus dose INCREASE
  - Monitor glucose very closely during steroid therapy
  - Reduce insulin when steroids discontinued
- **Source:** FDA Prescribing Information; Drugs.com

#### Atypical Antipsychotics
- **Interacting Drugs:** Olanzapine, Clozapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone, Iloperidone, Paliperidone, Haloperidol
- **Interaction Type:** Metabolic effects causing insulin resistance
- **Mechanism:** Weight gain; direct effects on glucose metabolism
- **Clinical Effect:** Worsened glycemic control; hyperglycemia
- **Management:** Monitor glucose closely; may need Lantus dose increase
- **Source:** Medscape Drug Interactions; Drugs.com

#### Sympathomimetics
- **Interacting Drugs:** Epinephrine, Norepinephrine, Albuterol, Salmeterol, Formoterol, Terbutaline, Pseudoephedrine, Phenylephrine, Dopamine, Dobutamine
- **Interaction Type:** Counter-regulatory hormone effect
- **Mechanism:** Stimulate glycogenolysis and gluconeogenesis via beta-adrenergic activation
- **Clinical Effect:** Hyperglycemia
- **Management:** May need temporary Lantus increase during prolonged use
- **Source:** FDA Prescribing Information; Drugs.com

#### Thyroid Hormones
- **Interacting Drugs:** Levothyroxine (Synthroid), Liothyronine, Thyroid desiccated
- **Interaction Type:** Pharmacodynamic antagonism
- **Mechanism:** Thyroid hormones increase glucose absorption and hepatic glucose output
- **Clinical Effect:** May worsen glycemic control in hyperthyroid states
- **Management:** Monitor glucose when initiating or adjusting thyroid medication
- **Source:** FDA Prescribing Information; Drugs.com

#### Diuretics
- **Interacting Drugs:**
  - Thiazides: Hydrochlorothiazide, Chlorthalidone, Indapamide
  - Loop: Furosemide, Bumetanide, Torsemide
- **Interaction Type:** Hyperglycemic effect
- **Mechanism:** May cause hyperglycemia; hypokalemia reduces insulin secretion
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor blood glucose and potassium
- **Source:** FDA Prescribing Information; Drugs.com

#### Estrogens and Oral Contraceptives
- **Interacting Drugs:** Ethinyl estradiol, Combined oral contraceptives, Conjugated estrogens
- **Interaction Type:** May impair glucose tolerance
- **Mechanism:** Estrogens may cause insulin resistance
- **Clinical Effect:** Possible decrease in glycemic control
- **Management:** Monitor blood glucose
- **Source:** FDA Prescribing Information; Medscape

#### Protease Inhibitors
- **Interacting Drugs:** Ritonavir, Atazanavir, Darunavir, Lopinavir, Indinavir, Nelfinavir
- **Interaction Type:** Metabolic effects
- **Mechanism:** May cause insulin resistance and hyperglycemia
- **Clinical Effect:** New-onset diabetes or worsened glycemic control
- **Management:** Monitor glucose closely; adjust Lantus as needed
- **Source:** Drugs.com Drug Interactions Database

#### Danazol
- **Interacting Drug:** Danazol
- **Interaction Type:** Hyperglycemic effect
- **Mechanism:** Causes insulin resistance
- **Clinical Effect:** Worsened glycemic control
- **Management:** Monitor glucose; increase Lantus as needed
- **Source:** Medscape Drug Interactions

#### Phenytoin
- **Interacting Drug:** Phenytoin (Dilantin)
- **Interaction Type:** Inhibits insulin secretion
- **Mechanism:** Direct effect on pancreatic beta cells
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor glucose closely; may need higher Lantus dose
- **Source:** FDA Prescribing Information

#### Nicotinic Acid (Niacin)
- **Interacting Drug:** Niacin (high-dose)
- **Interaction Type:** Impairs glucose tolerance
- **Mechanism:** Affects insulin sensitivity
- **Clinical Effect:** Hyperglycemia
- **Management:** Monitor glucose; adjust Lantus as needed
- **Source:** FDA Prescribing Information

### Drugs with Variable/Unpredictable Effects

#### Alcohol
- **Severity:** Moderate
- **Mechanism:** 
  - Inhibits hepatic gluconeogenesis → hypoglycemia
  - Adds calories → hyperglycemia
- **Clinical Effect:** Unpredictable glucose changes; primarily hypoglycemia with fasting
- **Management:** 
  - Avoid excessive alcohol
  - Do not drink on empty stomach
  - Monitor glucose
- **Source:** FDA Prescribing Information; Drugs.com

#### Clonidine
- **Interacting Drug:** Clonidine
- **Interaction Type:** Variable glucose effects; masks hypoglycemia symptoms
- **Mechanism:** May increase or decrease blood glucose; masks adrenergic symptoms
- **Clinical Effect:** Unpredictable glucose; masked hypoglycemia recognition
- **Management:** More frequent glucose monitoring
- **Source:** FDA Prescribing Information (Lantus)

#### Lithium
- **Interacting Drug:** Lithium
- **Interaction Type:** Variable glucose effects
- **Mechanism:** May either increase or decrease blood glucose
- **Clinical Effect:** Unpredictable glycemic effects
- **Management:** Monitor blood glucose closely
- **Source:** FDA Prescribing Information (Lantus)

#### Reserpine
- **Interacting Drug:** Reserpine
- **Interaction Type:** Masks hypoglycemia symptoms
- **Mechanism:** Depletes catecholamines
- **Clinical Effect:** Reduced awareness of hypoglycemia
- **Management:** Patient education; frequent monitoring
- **Source:** FDA Prescribing Information (Lantus)

#### Guanethidine
- **Interacting Drug:** Guanethidine
- **Interaction Type:** Masks hypoglycemia symptoms
- **Clinical Effect:** Reduced awareness of hypoglycemia
- **Management:** Careful monitoring
- **Source:** FDA Prescribing Information (Lantus)

---

## Drug-Food Interactions

### Alcohol
- **Severity:** Moderate
- **Mechanism:** Inhibits gluconeogenesis; unpredictable effects
- **Clinical Effect:** 
  - Hypoglycemia (especially fasting or after exercise)
  - Hyperglycemia (excess calories)
- **Recommendation:**
  - Moderate consumption only if diabetes well-controlled
  - Avoid if uncontrolled diabetes, neuropathy, pancreatitis, or high triglycerides
  - Always eat food when drinking
- **Source:** FDA Prescribing Information; Drugs.com Food Interactions

### Meals/Food
- **Lantus:** Can be given at any time regardless of meals
- **Timing:** Consistent timing recommended (same time each day)
- **Source:** FDA Prescribing Information

---

## Drug-Disease Interactions

### 1. Renal Impairment (Moderate)
- **Effect:** Reduced insulin clearance
- **Risk:** Prolonged hypoglycemia
- **Management:**
  - May need Lantus dose REDUCTION
  - Careful glucose monitoring
  - More frequent monitoring in patients with declining renal function
- **Source:** FDA Prescribing Information; Drugs.com

### 2. Hepatic Impairment (Moderate)
- **Effect:** 
  - Reduced gluconeogenesis capacity
  - Reduced insulin metabolism
- **Risk:** Increased hypoglycemia risk
- **Management:**
  - May need Lantus dose REDUCTION
  - Careful monitoring
- **Source:** FDA Prescribing Information; Drugs.com

### 3. Hypokalemia (Moderate)
- **Effect:** Insulin shifts potassium intracellularly
- **Risk:** Worsening hypokalemia; cardiac arrhythmias
- **At-Risk Situations:**
  - Concurrent loop diuretics
  - Concurrent thiazides
  - IV insulin infusions
- **Management:**
  - Monitor potassium levels
  - Correct hypokalemia
- **Source:** FDA Prescribing Information; Drugs.com

### 4. Hypoglycemia Risk (Moderate)
- **High-Risk Patients:**
  - Elderly
  - Patients with autonomic neuropathy (may not recognize symptoms)
  - Those with irregular eating patterns
  - Patients taking beta-blockers
  - Patients with renal/hepatic impairment
  - Debilitated or malnourished patients
- **Management:**
  - Individualized dosing
  - Patient education
  - Frequent monitoring
  - Lower initial doses in high-risk patients
- **Source:** FDA Prescribing Information; Drugs.com

### 5. Heart Failure (Moderate)
- **Concern:** Thiazolidinediones + insulin may worsen heart failure
- **Management:**
  - Use TZD + insulin combination with caution
  - Monitor for signs of heart failure
  - Avoid in severe heart failure
- **Source:** FDA Prescribing Information

### 6. Lipodystrophy/Localized Cutaneous Amyloidosis
- **Issue:** Can occur at injection sites
- **Effect:** May affect insulin absorption
- **Management:**
  - Rotate injection sites
  - Change injection site if lipodystrophy noted
  - Monitor for hypoglycemia when changing sites
- **Source:** FDA Prescribing Information

---

## Summary Statistics
- **Total Known Drug Interactions:** 407
- **Major Interactions:** 16
- **Moderate Interactions:** 363
- **Minor Interactions:** 28
- **Disease Interactions:** 3
- **Food/Alcohol Interactions:** 1

---

## Clinical Recommendations for Safe Use

1. **Before Starting Lantus:**
   - Establish baseline glucose levels
   - Assess renal and hepatic function
   - Review complete medication list for interactions
   - Identify patients at high hypoglycemia risk
   - Assess potassium level if on diuretics

2. **Dosing:**
   - Type 1: Start ~⅓ of total daily insulin dose as Lantus; use meal-time insulin for remaining ⅔
   - Type 2 (insulin-naïve): Start 0.2 units/kg OR 10 units once daily
   - Administer at same time each day
   - Do NOT mix or dilute
   - Do NOT use in insulin pumps

3. **Administration:**
   - Subcutaneous injection only (NOT IV, NOT IM)
   - Injection sites: Abdomen, thigh, upper arm
   - Rotate sites to prevent lipodystrophy
   - Never share pens/syringes between patients

4. **Monitoring:**
   - Regular blood glucose monitoring (SMBG)
   - Periodic HbA1c
   - Watch for hypoglycemia symptoms
   - Monitor potassium if on diuretics
   - Renal function periodically

5. **Dose Adjustments with Interacting Drugs:**
   - INCREASE Lantus during corticosteroid therapy
   - DECREASE Lantus with ACE inhibitors if hypoglycemia occurs
   - DECREASE when adding other antidiabetic agents
   - Adjust for renal/hepatic impairment

6. **Patient Education:**
   - Never share insulin pens
   - Recognize and treat hypoglycemia
   - Carry glucose tablets
   - Sick day management
   - Storage (refrigerate unused; room temp ok for 28 days in use)
   - Signs of severe hypoglycemia requiring assistance
   - When to contact healthcare provider

7. **When to Adjust Therapy:**
   - Starting/stopping interacting medications
   - Changes in diet or exercise
   - Acute illness
   - Changes in renal or hepatic function
   - Pregnancy planning

---

## Brand Comparisons (Insulin Glargine Products)
| Product | Concentration | Biosimilar? | Notes |
|---------|--------------|-------------|-------|
| Lantus | 100 units/mL | Reference | Original |
| Lantus SoloStar | 100 units/mL | Reference | Pen device |
| Basaglar | 100 units/mL | Yes | Biosimilar |
| Semglee | 100 units/mL | Yes | Interchangeable biosimilar |
| Rezvoglar | 100 units/mL | Yes | Interchangeable biosimilar |
| Toujeo | 300 units/mL | No | Concentrated; NOT equivalent unit-for-unit |

**Note:** Toujeo (U-300) is NOT unit-for-unit equivalent to U-100 products. Conversion requires dose adjustment.

---

## References
1. FDA Prescribing Information - Lantus (Insulin Glargine)
2. Drugs.com Drug Interactions Database (https://www.drugs.com/drug-interactions/insulin-glargine,lantus.html)
3. Medscape Drug Interactions Reference
4. RxList - Lantus Drug Information
5. Medical News Today - Lantus Interactions
6. MedBroadcast - Lantus Interactions
7. American Diabetes Association Standards of Care
8. FDA Prescribing Information - Toujeo
9. FDA Prescribing Information - Basaglar
